{"filing":{"accession_number":"0001140361-26-023397","cik":"0000320017","ticker":"LSTA","company_name":"LISATA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"ef20075280_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036126023397/ef20075280_8k.htm"},"events":[{"id":7739,"run_id":6800,"accession_number":"0001140361-26-023397","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses a material amendment to a merger agreement and a critical delay in the commencement of a tender offer. Parent (Kuva Labs) informed Lisata on May 31, 2026 that it will not commence the previously scheduled June 1, 2026 tender offer, citing ongoing financing negotiations. This represents a material development in the proposed acquisition transaction that would significantly affect investor assessment of the deal's timing and likelihood of completion.","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3057,"accession_number":"0001140361-26-023397","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a material amendment to a merger agreement and a critical delay in the commencement of a tender offer. Parent (Kuva Labs) informed Lisata on May 31, 2026 that it will not commence the previously scheduled June 1, 2026 tender offer, citing ongoing financing negotiations. This represents a material development in the proposed acquisition transaction that would significantly affect investor assessment of the deal's timing and likelihood of completion.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:18:02.857097+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3057,"accession_number":"0001140361-26-023397","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a material amendment to a merger agreement and a critical delay in the commencement of a tender offer. Parent (Kuva Labs) informed Lisata on May 31, 2026 that it will not commence the previously scheduled June 1, 2026 tender offer, citing ongoing financing negotiations. This represents a material development in the proposed acquisition transaction that would significantly affect investor assessment of the deal's timing and likelihood of completion.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:18:02.857097+00:00","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-06-01"}]}